

# Igor T Gavrilovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1966528/publications.pdf>

Version: 2024-02-01

29  
papers

2,805  
citations

394421

19  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4386  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.	1.2	6
2	Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. <i>BMC Cancer</i> , 2022, 22, 60.	2.6	5
3	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	1.2	56
4	Clinical Experience of Cerebrospinal Fluidâ€Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	2.8	17
5	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436.	3.7	29
6	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	1.8	24
7	Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 145, 57-63.	2.9	10
8	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.	2.9	55
9	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
10	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	1.6	39
11	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
12	Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , 2017, 4, 24-28.	1.6	4
13	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 735-743.	1.2	28
14	A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. <i>Neuro-Oncology</i> , 2016, 18, 873-880.	1.2	72
15	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.	1.4	267
16	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	1.2	207
17	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
18	In Reply. <i>Oncologist</i> , 2013, 18, e18.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.	1.2	83
20	Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment. <i>Oncologist</i> , 2012, 17, 274-278.	3.7	30
21	Temozolomide or bevacizumab for spinal cord high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 385-389.	2.9	42
22	Pearls: Primary Brain Tumors. <i>Seminars in Neurology</i> , 2010, 30, 005-009.	1.4	1
23	Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867.	1.6	159
24	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90.	2.9	40
25	Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 85, 217-222.	2.9	15
26	Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4570-4574.	1.6	287
27	Diagnosis and treatment of primary central nervous system lymphoma. <i>Current Oncology Reports</i> , 2005, 7, 47-54.	4.0	7
28	Brain metastases: epidemiology and pathophysiology. <i>Journal of Neuro-Oncology</i> , 2005, 75, 5-14.	2.9	816
29	Primary central nervous system lymphoma. <i>Current Oncology Reports</i> , 2004, 6, 388-395.	4.0	5